The burgeoning interest in NAD+ formulations, particularly at significant doses like 1000mg, is linked with the developing profile of Retatrutide – a novel GLP-1 receptor activator gaining attention https://bookmarkfox.com/story8011194/nad-product-the-new-drug-a-british-focus